XML 54 R10.htm IDEA: XBRL DOCUMENT v2.4.1.9
Going Concern
3 Months Ended
Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Going Concern

NOTE 4. GOING CONCERN

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. Exclusive of a onetime non-cash gain of $41,645,688 recognized upon the deconsolidation of Entest Biomedical, Inc., the Company generated net losses of $19,377, 575 (excluding $663,649 of Equity in Net Losses of Entest Biomedical, Inc. recognized) during the period from August 2, 2005 (inception) through December 31, 2014. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Management plans to raise additional funds by offering securities for cash.

 

During the quarter ended December 31, 2014 the Company incurred borrowings of $217,321

 

During the quarter ended December 31, 2014 the Company sold 666,668 of its owned shares of Regen Biopharma, Inc. for consideration of $50,000.

 

During the quarter ended December 31, 2014 the Company the company entered into a binding contract to sell 266,667 of the Company’s owned shares of Regen Biopharma, Inc. for consideration of $20,000. Payment was received by the Company on December 23, 2014. As of December 31, 2014 the shares have not been transferred to the purchaser.